跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 14,196 条关于
“Hypothalamic Obesity”
全部
14,196
临床试验
12,275
药物
83
机构
10
资讯
1,828
去年
Setmelanotide Receives Orphan Drug Designation in Japan for Hypothalamic Obesity Treatment
去年
Rhythm's Imcivree Shows Significant Weight Loss in Patients with Hypothalamic Obesity
去年
Rhythm Pharmaceuticals' Setmelanotide Shows Breakthrough Results in Rare Hypothalamic Obesity Trial
去年
Rhythm Pharmaceuticals' Imcivree Shows Significant Weight Loss in Phase III Hypothalamic Obesity Trial
8个月前
Rhythm Pharmaceuticals Faces FDA Delay for Setmelanotide in Hypothalamic Obesity as Stock Retreats from 2025 Highs
去年
Rhythm Pharmaceuticals Reports Strong Q3 2024 Driven by IMCIVREE Sales, Advances Hypothalamic Obesity Program
10个月前
Palatin Advances Oral MC4R Agonist PL7737 for Obesity Treatment with Promising Preclinical Data
10个月前
Rhythm Pharmaceuticals Reports Strong Q3 2025 Results with $51.3M IMCIVREE Revenue and December FDA Decision Pending
去年
Jefferies Initiates Coverage on Rhythm Pharmaceuticals with Bullish Outlook on Obesity Drug Pipeline
10个月前
Palatin Technologies Advances Melanocortin-Based Obesity Pipeline with $18.2M Funding and Boehringer Ingelheim Partnership
第 1 页,共 183 页
上一页
下一页